Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis

Alzheimer's and Dementia

Volumn 13, Issue 8, 2017, Pages 841-849

  Ovod, Vitaliy ^a   Ramsey, Kara N ^a   Mawuenyega, Kwasi G ^a   Bollinger, Jim G ^a   Hicks, Terry ^a   Schneider, Theresa ^a   Sullivan, Melissa ^a   Paumier, Katrina ^a   Holtzman, David M ^a   Morris, John C ^a   Benzinger, Tammie ^a   Fagan, Anne M ^a   Patterson, Bruce W ^a   Bateman, Randall J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amyloid ; A 42; Human; Kinetics; Plasma; Turnover

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PROTEIN; BIOLOGICAL MARKER; STABLE ISOTOPE; UNCLASSIFIED DRUG; AMYLOID BETA-PROTEIN (1-38); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

AGED; AMYLOIDOSIS; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM AMYLOIDOSIS; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; HALF LIFE TIME; HUMAN; ISOTOPE LABELING; KINETICS; PLASMA; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN STABILITY; SENSITIVITY ANALYSIS; AREA UNDER THE CURVE; BLOOD; DIAGNOSTIC IMAGING; IMMUNOPRECIPITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SINGLE BLIND PROCEDURE;

AGED; AMYLOID BETA-PEPTIDES; AMYLOIDOSIS; AREA UNDER CURVE; BIOMARKERS; CHROMATOGRAPHY, LIQUID; HUMANS; IMMUNOPRECIPITATION; ISOTOPE LABELING; KINETICS; MASS SPECTROMETRY; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; ROC CURVE; SINGLE-BLIND METHOD;

EID: 85024891505     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2017.06.2266     Document Type: Article

References (17)

1. Selkoe, D.J., Hardy, J., The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 8 (2016), 595–608.
2. Potter, R., Patterson, B.W., Elbert, D.L., Ovod, V., Kasten, T., Sigurdson, W., et al. Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med, 5, 2013, 189ra77.
3. Patterson, B.W., Elbert, D.L., Mawuenyega, K.G., Kasten, T., Ovod, V., Ma, S., et al. Age and amyloid effects on human CNS amyloid-beta kinetics. Ann Neurol 78 (2015), 439–453.
4. Beach, T.G., Monsell, S.E., Phillips, L.E., Kukull, W., Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer's disease Centers, 2005-2010. J Neuropathol Exp Neurol 71 (2013), 266–273.
5. Cohen, A.D., Klunk, W.E., Early detection of Alzheimer's disease using PiB and FDG PET. Neurobiol Dis 72 Pt A (2014), 117–122.
6. Galasko, D., Chang, L., Motter, R., Clark, C.M., Kaye, J., Knopman, D., et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55 (1998), 937–945.
7. Clark, C.M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch Neurol 60 (2003), 1696–1702.
8. Mayeux, R., Honig, L.S., Tang, M.X., Manly, J., Stern, Y., Schupf, N., et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61 (2003), 1185–1190.
9. Yaffe, K., Weston, A., Graff-Radford, N.R., Satterfield, S., Simonsick, E.M., Younkin, S.G., et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 305 (2011), 261–266.
10. Bateman, R.J., Munsell, L.Y., Morris, J.C., Swarm, R., Yarasheski, K.E., Holtzman, D.M., Human amyloid-B synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 12 (2006), 856–861.
11. Mawuenyega, K.G., Kasten, T., Sigurdson, W., Bateman, R.J., Amyloid-beta isoform metabolism quantitation by stable isotope-labeled kinetics. Anal Biochem 440 (2013), 56–62.
12. Roberts, K.F., Elbert, D.L., Kasten, T.P., Patterson, B.W., Sigurdson, W.C., Connors, R.E., et al. Amyloid-B efflux from the CNS into the plasma. Ann Neurol 76 (2014), 837–844.
13. Deane, R., Du Yan, S., Submamaryan, R.K., LaRue, B., Jovanovic, S., Hogg, E., et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9 (2003), 907–913.
14. Dean, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 5 (2004), 333–344.
15. Fukumoto, H., Tennis, M., Locascio, J.J., Hyman, B.T., Grwodon, J.H., Irizarry, M.C., Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 60 (2003), 958–964.
16. Sobów, T., Flirski, M., Kłoszewska, I., Liberski, P.P., Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiol Exp (Wars) 65 (2005), 117–124.
17. Mayeux, R., Schupf, N., Blood-based biomarkers for Alzheimer's disease: plasma Ab40 and AB42, and genetic variants. Neurobiol Aging 32 (2011), S10–S19.